Authorized purpose: Ultrasound System 2300 provides diagnostic ultrasound, fluid-flow analysis, and puncture or biopsy guidance across fetal and obstetric, abdominal, pediatric, intraoperative, small-organ, cardiac, transesophageal, vascular, musculoskeletal, thoracic, and transrectal or transvaginal applications; it is not for ophthalmic imaging or through-the-eye use.
Clinical role
Ultrasound acquisition, measurement, analysis, reporting, and release-specific AI assistance.
Images and patients
Ultrasound · Multi-region
Key limitation
Keep in mind: The system is not intended for ophthalmic use or any use causing the acoustic beam to pass through the eye; the Cardiac Adult application is not intended for direct use on the heart.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Ultrasound System 2300 provides diagnostic ultrasound, fluid-flow analysis, and puncture or biopsy guidance across fetal and obstetric, abdominal, pediatric, intraoperative, small-organ, cardiac, transesophageal, vascular, musculoskeletal, thoracic, and transrectal or transvaginal applications; it is not for ophthalmic imaging or through-the-eye use.
Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Multi-region Input: Ultrasound imaging acquired with the system's supported configurations and transducers.
Who uses it?Intended users: Qualified and trained healthcare professionals.
What does the software produce?Output: Processed and displayed ultrasound images with measurements/calculations and biopsy-guidance visualizations.
What is its most important limitation?Key limitation: The system is not intended for ophthalmic use or any use causing the acoustic beam to pass through the eye; the Cardiac Adult application is not intended for direct use on the heart.
Clinical takeaway. Clinical role: Ultrasound System 2300 provides diagnostic ultrasound, fluid-flow analysis, and puncture or biopsy guidance across fetal and obstetric, abdominal, pediatric, intraoperative, small-organ, cardiac, transesophageal, vascular, musculoskeletal, thoracic, and transrectal or transvaginal applications; it is not for ophthalmic imaging or through-the-eye use.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports performance and safety verification testing and testing of the AI Prostate Volume Assist feature on two data sets not part of training, comparing automatic initial caliper placement with manual placement: prostate volume deviated 11% +/- 6% for the 9018 transducer and is expected to deviate 7% +/- 15% for the 9048, against an acceptance criterion of no more than 22% on average; clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Ultrasound System 2300 provides diagnostic ultrasound, fluid-flow analysis, and puncture or biopsy guidance across fetal and obstetric, abdominal, pediatric, intraoperative, small-organ, cardiac, transesophageal, vascular, musculoskeletal, thoracic, and transrectal or transvaginal applications; it is not for ophthalmic imaging or through-the-eye use.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Processed and displayed ultrasound images with measurements/calculations and biopsy-guidance visualizations.
Exact FDA submission
Checked 2026-09-19
The exact packet supports acquisition, processing, display, measurements/calculations, and needle-guide visualization but not the broader reports/overlays wording.
The system is not intended for ophthalmic use or any use causing the acoustic beam to pass through the eye; the Cardiac Adult application is not intended for direct use on the heart.
Exact FDA submission
Checked 2026-09-19
These are the exact contraindication statements in the packet.
The exact FDA document reports performance and safety verification testing and testing of the AI Prostate Volume Assist feature on two data sets not part of training, comparing automatic initial caliper placement with manual placement: prostate volume deviated 11% +/- 6% for the 9018 transducer and is expected to deviate 7% +/- 15% for the 9048, against an acceptance criterion of no more than 22% on average; clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "• Performance testing (Verification) • Safety testing (Verification) AI Feature Summary of Testing – Prostate Volume Assist (PVA)" … "For testing, we use two data sets that have not been part of the training of the algorithm. Data from a clinical end-user test in the Czech Republic was being used to represent the 9018 transducer". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports performance and safety verification testing and testing of the AI Prostate Volume Assist feature on two data sets not part of training, comparing automatic initial caliper placement with manual placement: prostate volume deviated 11% +/- 6% for the 9018 transducer and is expected to deviate 7% +/- 15% for the 9048, against an acceptance criterion of no more than 22% on average; clinical studies were not required. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "• Performance testing (Verification) • Safety testing (Verification) AI Feature Summary of Testing – Prostate Volume Assist (PVA)" … "For testing, we use two data sets that have not been part of the training of the algorithm. Data from a clinical end-user test in the Czech Republic was being used to represent the 9018 transducer". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K223830 FDA performance package for Ultrasound System 2300
DesignManufacturer ultrasound-system, probe, software, image-quality, Doppler, and workflow verification and validation
PopulationAdult, pediatric, fetal, obstetric, cardiac, vascular, thoracic, procedural, and other labeled ultrasound applications
Scopeexact submission
Tested versionUltrasound System 2300
IndependenceSponsor or vendor study
K223830
Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
6 exact-submission FDA recall records in the 2026-09-02 openFDA snapshot identify K223830. Affected model, version, unit, correction, and current manufacturer instructions still require local confirmation. FDA recall Z-0437-2026 is Open, Classified for UUltrasound System 2300, bkActiv w/battery; Model No. 2300-11; System, Imaging, Pulsed Doppler, Ultrasonic. FDA reason: GE HealthCare has become aware that the Instructions for Use within the user guide and service manual do not adequately state the required battery replacement intervals, end-of-life handling procedures, or general battery safety precautions. FDA action: GE Healthcare issued an "URGENT MEDICAL DEVICE CORRECTION NOTICE" to its consignees on 10/09/2025 via traceable means. The notice explained the issue, potential risk, and requested: "Actions to be taken by Customer / User You can continue to use your device by following the instructions below: 1. Review and follow the applicable addendums to the Instructions for Use and the updated Service Manuals. The Addendums and Service Manuals are available for download at: https://www.gehealthcare.com/support/manuals. 2. Follow the conditions defined within the addendum and Service Manual applicable to your product for further instructions. 3. Place the applicable addendum and Service Manual with your existing product Instructions for Use. 4. If you have difficulty accessing the documentation or require a printed copy of the applicable addendum or Service Manual, please contact a GE HealthCare Service Representative for assistance. Please ensure all potential users in your facility are made aware of this safety notification and the required actions. Please retain this document for your records." For questions or concerns regarding this notification, please contact GE HealthCare at 1-800-645-4442 or bksupport.us@gehealthcare.com or your local Service Representative. FDA recall Z-0438-2026 is Open, Classified for bk3000 Ultrasound System w/battery; Model No. 2300-66; System, Imaging, Pulsed Doppler, Ultrasonic. FDA reason: GE HealthCare has become aware that the Instructions for Use within the user guide and service manual do not adequately state the required battery replacement intervals, end-of-life handling procedures, or general battery safety precautions. FDA action: GE Healthcare issued an "URGENT MEDICAL DEVICE CORRECTION NOTICE" to its consignees on 10/09/2025 via traceable means. The notice explained the issue, potential risk, and requested: "Actions to be taken by Customer / User You can continue to use your device by following the instructions below: 1. Review and follow the applicable addendums to the Instructions for Use and the updated Service Manuals. The Addendums and Service Manuals are available for download at: https://www.gehealthcare.com/support/manuals. 2. Follow the conditions defined within the addendum and Service Manual applicable to your product for further instructions. 3. Place the applicable addendum and Service Manual with your existing product Instructions for Use. 4. If you have difficulty accessing the documentation or require a printed copy of the applicable addendum or Service Manual, please contact a GE HealthCare Service Representative for assistance. Please ensure all potential users in your facility are made aware of this safety notification and the required actions. Please retain this document for your records." For questions or concerns regarding this notification, please contact GE HealthCare at 1-800-645-4442 or bksupport.us@gehealthcare.com or your local Service Representative. FDA recall Z-0439-2026 is Open, Classified for bk3500 Ultrasound System w/battery; Model No. 2300-41; System, Imaging, Pulsed Doppler, Ultrasonic. FDA reason: GE HealthCare has become aware that the Instructions for Use within the user guide and service manual do not adequately state the required battery replacement intervals, end-of-life handling procedures, or general battery safety precautions. FDA action: GE Healthcare issued an "URGENT MEDICAL DEVICE CORRECTION NOTICE" to its consignees on 10/09/2025 via traceable means. The notice explained the issue, potential risk, and requested: "Actions to be taken by Customer / User You can continue to use your device by following the instructions below: 1. Review and follow the applicable addendums to the Instructions for Use and the updated Service Manuals. The Addendums and Service Manuals are available for download at: https://www.gehealthcare.com/support/manuals. 2. Follow the conditions defined within the addendum and Service Manual applicable to your product for further instructions. 3. Place the applicable addendum and Service Manual with your existing product Instructions for Use. 4. If you have difficulty accessing the documentation or require a printed copy of the applicable addendum or Service Manual, please contact a GE HealthCare Service Representative for assistance. Please ensure all potential users in your facility are made aware of this safety notification and the required actions. Please retain this document for your records." For questions or concerns regarding this notification, please contact GE HealthCare at 1-800-645-4442 or bksupport.us@gehealthcare.com or your local Service Representative. FDA recall Z-0440-2026 is Open, Classified for bk5000 Ultrasound System w/battery; Model No. 2300-61; System, Imaging, Pulsed Doppler, Ultrasonic. FDA reason: GE HealthCare has become aware that the Instructions for Use within the user guide and service manual do not adequately state the required battery replacement intervals, end-of-life handling procedures, or general battery safety precautions. FDA action: GE Healthcare issued an "URGENT MEDICAL DEVICE CORRECTION NOTICE" to its consignees on 10/09/2025 via traceable means. The notice explained the issue, potential risk, and requested: "Actions to be taken by Customer / User You can continue to use your device by following the instructions below: 1. Review and follow the applicable addendums to the Instructions for Use and the updated Service Manuals. The Addendums and Service Manuals are available for download at: https://www.gehealthcare.com/support/manuals. 2. Follow the conditions defined within the addendum and Service Manual applicable to your product for further instructions. 3. Place the applicable addendum and Service Manual with your existing product Instructions for Use. 4. If you have difficulty accessing the documentation or require a printed copy of the applicable addendum or Service Manual, please contact a GE HealthCare Service Representative for assistance. Please ensure all potential users in your facility are made aware of this safety notification and the required actions. Please retain this document for your records." For questions or concerns regarding this notification, please contact GE HealthCare at 1-800-645-4442 or bksupport.us@gehealthcare.com or your local Service Representative. FDA recall Z-0136-2025 is Open, Classified for bk3000, model #2300-11; bk3500, model #2300-41; bk5000, model #2300-61; and bkActive 2300, model #2300-66, ultrasound system with battery option.. FDA reason: The internal power connections at the power inlet of the ultrasound devices can come loose resulting in the potential for excessive heat which could lead to a thermal event or the device becoming inoperable. FDA action: Notifications were issued on and dated 9/4/2024 informing the consignee of the safety issue and the actions to be taken, which included: Until GE HealthCare implements a permanent correction on the device for this issue, the consignee is to inspect the power cord connection at the power inlet to the ultrasound device. A photograph of the area to be inspected was embedded in the letter. If a cord retaining bracket is not present, the consignee is to ensure the power cord is fully pushed into the power inlet before each use and while the ultrasound device is charging. If a cord retaining bracket is present, no further action is required. The consignee is to ensure all potential staff in the facility are made aware of the safety notification and the recommended actions. An acknowledgment form was enclosed for completion and return. FDA recall Z-0813-2024 is Open, Classified for bkActiv Ultrasound System 2300, Model numbers 2300-56 and 2300-66.. FDA reason: An issue on the Dual Live Compare feature on the bkActiv system could result in a measurement error. FDA action: The firm issued letters dated 11/30/2023 via FedEx to the following titles at the consignee locations: Head of Surgical Operations, Head of Ultrasound Department, Hospital Administrator / Risk Managers, and Head of Clinical Engineering. The letter explained the issue and informed the consignee they can continue to use the ultrasound system. Before using the Dual Live Compare, they are to consult the user manual (specific site provided) to ensure that the scanning depth in the Live image is the same as the Stored image. Photographs of the bkActiv screen were provided for the consignee to view. The consignee is to ensure all potential users in the facility are made are of the correction notification and the recommended actions. A link was provided for the acknowledgment form for the consignee to complete and return. All bkActive (2300-56 and 2300-66) Ultrasound Systems are affected but an appendix was provided containing a list of all affected serial numbers. The consignee was informed BK Medical will correct all affected products and a representative will contact the consignee to schedule a service visit to correct the issue.
FDA source
Exact FDA submission
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; do not infer an AI-algorithm defect unless the FDA record says so. Confirm affected model, version, units, corrective action, and completion status locally.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; do not infer an AI-algorithm defect unless the FDA record says so. Confirm affected model, version, units, corrective action, and completion status locally.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; do not infer an AI-algorithm defect unless the FDA record says so. Confirm affected model, version, units, corrective action, and completion status locally.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; do not infer an AI-algorithm defect unless the FDA record says so. Confirm affected model, version, units, corrective action, and completion status locally.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; do not infer an AI-algorithm defect unless the FDA record says so. Confirm affected model, version, units, corrective action, and completion status locally.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; do not infer an AI-algorithm defect unless the FDA record says so. Confirm affected model, version, units, corrective action, and completion status locally.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Ultrasound imaging acquired with the system's supported configurations and transducers.
Scope: Exact FDA submission. The exact device description establishes digital acquisition and supported transducers; it does not establish imported ultrasound data.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Ultrasound hardware or software with supported probes, host devices, licensed options, and network configuration.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Processed and displayed ultrasound images with measurements/calculations and biopsy-guidance visualizations.
Scope: Exact FDA submission. The exact packet supports acquisition, processing, display, measurements/calculations, and needle-guide visualization but not the broader reports/overlays wording.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Processed and displayed ultrasound images with measurements/calculations and biopsy-guidance visualizations.
Scope: Exact FDA submission. The exact packet supports acquisition, processing, display, measurements/calculations, and needle-guide visualization but not the broader reports/overlays wording.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
Only qualified physicians, sonographers, and other trained ultrasound professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only labeled probes, modes, anatomies, patient populations, and guidance workflows. The system is not for ophthalmic imaging or through-the-eye use; the operator must confirm image quality and procedural anatomy.
Validate supported probes and host devices, patient matching, DICOM or local export, PACS measurements, worklist, report transfer, and offline or downtime behavior.
exact submission · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. The capability is derived from the exact FDA workflow and still requires local acceptance testing.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use only labeled probes, modes, anatomies, patient populations, and guidance workflows. The system is not for ophthalmic imaging or through-the-eye use; the operator must confirm image quality and procedural anatomy.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only labeled probes, modes, anatomies, patient populations, and guidance workflows. The system is not for ophthalmic imaging or through-the-eye use; the operator must confirm image quality and procedural anatomy.
exact submission · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. The capability is derived from the exact FDA workflow and still requires local acceptance testing.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
28Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 6 FDA recall candidates were manually reviewed: 6 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 6 postmarket candidate records; 6 have been reviewed (6 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-03 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Ge Medical Systems Ultrasound and Primary Care Diagnostics
Authorized purpose: LOGIQ E10s is a general-purpose diagnostic ultrasound system supporting the labeled adult, pediatric, cardiac, vascular, abdominal, obstetric, small-organ, musculoskeletal, urologic, and procedural applications.
Ge Medical Systems Ultrasound and Primary Care Diagnostics
Authorized purpose: LOGIQ E10 is a general diagnostic ultrasound system for qualified users across fetal and obstetric, abdominal, gynecologic, pediatric, small-organ, breast, cardiac, vascular, musculoskeletal, urologic, transrectal, transvaginal, transesophageal, and intraoperative applications.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.